J Clin Oncol 2012 Jan 20
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Related Questions
Will you treat only the anastamosis and remnant stomach without elective nodal RT, or will you include elective nodal RT in your treatment fields, ass...
New answer by Radiation Oncologist at Brigham and Women's Hospital (June 6, 2018)
INT-0116 remains the only positive phase III trial showing a benefit to adjuvant chemoradiation for gastric cancer. Though very few of those patients had D2 dissections, unpla...
Detailed instructions regarding lymph node coverage have been published, but how do you think about coverage of the anastamoses from the gastrectomy?
New comment by Radiation Oncologist at UTHSCSA ( January 1, 2019)
Great answer! I think Critics 2 will be a good study. Could you elaborate what you found about CRITICS that didn’t answer the question well enough?
The CRITICS trial showed there was no OS or PFS benefit with adj chemo vs CRT. Is there potentially still a role for CRT to reduce heme toxicity and p...
New comment by Radiation Oncologist at Memorial Sloan Kettering Cancer Center ( June 18, 2020)
These are all great questions without clear-cut answers. Typically if a patient did not have neoadjuvant chemotherapy, I prefer to give adjuvant CRT (if indicated, of course) ...
Exploratory analysis of the MAGIC trial suggested perioperative chemotherapy was detrimental in this subset of patients. Has availability of IO altere...
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (July 23, 2023)
As ever, @Sam provides an exhaustive analysis of this topic and has the receipts/references to back it up.I would approach this answer with a slightly different emphasis....